Unger S - Search Results

1

Absolute and relative bioavailability of the HMG-CoA reductase inhibitor cerivastatin.

Mück W, Ritter W, Ochmann K, Unger S, Ahr G, Wingender W, Kuhlmann J. Mück W, et al. Among authors: unger s. Int J Clin Pharmacol Ther. 1997 Jun;35(6):255-60. Int J Clin Pharmacol Ther. 1997. PMID: 9208342 Clinical Trial.

2

Pharmacokinetics and safety of nifedipine GITS/candesartan fixed-dose combination in subjects with hepatic impairment .

Liu Y, Boettcher MF, Schmidt A, Unger S, Halabi A, Brendel E, Blode H. Liu Y, et al. Among authors: unger s. Int J Clin Pharmacol Ther. 2017 Mar;55(3):246-255. doi: 10.5414/CP202700. Int J Clin Pharmacol Ther. 2017. PMID: 28025965 Clinical Trial.

3

Effects of omeprazole and aluminum hydroxide/magnesium hydroxide on riociguat absorption.

Becker C, Frey R, Unger S, Artmeier-Brandt U, Weimann G, Mück W. Becker C, et al. Among authors: unger s. Pulm Circ. 2016 Mar;6(Suppl 1):S43-8. doi: 10.1086/682228. Pulm Circ. 2016. PMID: 27162626 Free PMC article.

4

Pharmacokinetics of the soluble guanylate cyclase activator cinaciguat in individuals with hepatic impairment.

Frey R, Scheerans C, Blunck M, Mück W, Gnoth MJ, Unger S, Schmidt A, Wensing G. Frey R, et al. Among authors: unger s. J Clin Pharmacol. 2012 Nov;52(11):1714-24. doi: 10.1177/0091270011426143. Epub 2011 Dec 12. J Clin Pharmacol. 2012. PMID: 22162535 Clinical Trial.

5

Pharmacokinetic interaction study between riociguat and the combined oral contraceptives levonorgestrel and ethinylestradiol in healthy postmenopausal women.

Frey R, Unger S, van der Mey D, Becker C, Saleh S, Wensing G, Mück W. Frey R, et al. Among authors: unger s. Pulm Circ. 2016 Mar;6(Suppl 1):S97-S102. doi: 10.1086/685428. Pulm Circ. 2016. PMID: 27162633 Free PMC article.

6

Bioavailability, pharmacokinetics, and safety of riociguat given as an oral suspension or crushed tablet with and without food.

Saleh S, Frey R, Becker C, Unger S, Wensing G, Mück W. Saleh S, et al. Among authors: unger s. Pulm Circ. 2016 Mar;6(Suppl 1):S66-74. doi: 10.1086/685020. Pulm Circ. 2016. PMID: 27162630 Free PMC article.

7

Riociguat (BAY 63-2521) and aspirin: a randomized, pharmacodynamic, and pharmacokinetic interaction study.

Frey R, Reber M, Krätzschmar J, Unger S, Mück W, Wensing G. Frey R, et al. Among authors: unger s. Pulm Circ. 2016 Mar;6(Suppl 1):S35-42. doi: 10.1086/685014. Pulm Circ. 2016. PMID: 27162625 Free PMC article.

8

Absorption of riociguat (BAY 63-2521): bioavailability, food effects, and dose proportionality.

Becker C, Frey R, Hesse C, Unger S, Reber M, Mück W. Becker C, et al. Among authors: unger s. Pulm Circ. 2016 Mar;6(Suppl 1):S27-34. doi: 10.1086/685018. Pulm Circ. 2016. PMID: 27096084 Free PMC article.

9

Pharmacokinetics of the Soluble Guanylate Cyclase Stimulator Riociguat in Healthy Young Chinese Male Non-Smokers and Smokers: Results of a Randomized, Double-Blind, Placebo-Controlled Study.

Zhao X, Wang Z, Wang Y, Zhang H, Blode H, Yoshikawa K, Becker C, Unger S, Frey R, Cui Y. Zhao X, et al. Among authors: unger s. Clin Pharmacokinet. 2016 May;55(5):615-24. doi: 10.1007/s40262-015-0337-4. Clin Pharmacokinet. 2016. PMID: 26507720 Clinical Trial.

10

Pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase activator cinaciguat (BAY 58-2667) in healthy male volunteers.

Frey R, Mück W, Unger S, Artmeier-Brandt U, Weimann G, Wensing G. Frey R, et al. Among authors: unger s. J Clin Pharmacol. 2008 Dec;48(12):1400-10. doi: 10.1177/0091270008322906. Epub 2008 Sep 8. J Clin Pharmacol. 2008. PMID: 18779378 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results